Small caps can spend years being valued mainly on what might happen next. A mineral explorer talks about targets, a developer talks about future production, and a specialist technology business talks about the size of its addressable market. Eventually, though, the story has to become measurable through drilling results, funded development, production, contracts or revenue.
That is where the four companies we discuss today now sit. East Star Resources (LON: EST) has secured external partners prepared to fund substantial exploration and development work; Forgent Plc (AIM: FORG) has moved quickly from restructuring into repeated drilling, Bezant Resources (AIM: BZT) is advancing Hope & Gorob towards production, and Physiomics Plc (AIM: PYC) has started turning a commercial reset into a run of new contract awards. None has removed the risks attached to a small listed company, but all four now have clearer evidence against which progress can be judged.
The shift is particularly important because execution changes the nature of the investment case. East Star’s Verkhuba partner has committed to an estimated US$65 million development programme, Forgent has already completed 40 Phase 1 holes at Peak Hill, and Bezant has carried out the first blast at Hope & Gorob. Physiomics, meanwhile, has announced more than £750,000 of new contract awards in a little over four months.
That does not mean the hard work is finished. In many ways it means the opposite, because expectations now move from potential towards delivery. The next stage is about whether partner funded projects advance on schedule, drilling produces scale, a mine begins generating concentrate, and new contracts turn into recognised revenue and ultimately profit.
Four Companies, Four Different Ways of Proving the Story
East Star Resources is trying to prove that a junior explorer can retain meaningful exposure while much larger partners fund the expensive work. Its year end results highlighted both the Verkhuba agreement with Xinhai and the gold joint venture with Endeavour Mining, giving East Star two separate externally funded routes to value creation. The company has since added a second copper joint venture at Rulikha, making partner funded execution central to the investment case rather than a one off transaction.
Forgent is following a much faster exploration led route. At Peak Hill, Phase 1 drilling was completed in July with 2,680 metres drilled across 40 holes, before the company moved directly into an enlarged Phase 2 programme. By September, the Phase 2 campaign had been expanded to around 9,540 metres, reflecting management’s decision to follow up early results rather than slow the programme down.
Bezant Resources is already much closer to the point where investors can judge a mining operation rather than a development plan. Its Hope & Gorob project in Namibia recorded a roughly sevenfold increase in the open pittable Hope resource in April, followed in August by a 20,000 tonne blast that liberated around 2,000 tonnes of commercially viable mineralisation. The next evidence investors need is not another resource estimate, but plant throughput, concentrate production and cash generation.
Physiomics has a different measure of proof altogether. Its recent progress is commercial rather than geological, with more than £205,000 of new awards announced in September on top of contracts secured earlier in the summer. The aggregate value of contracts announced since May has now exceeded £750,000, equivalent to around 95% of the revenue reported for the whole of the previous financial year. Its challenge is therefore whether this burst of demand can become repeat business, higher recognised revenue and ultimately a sustainable profit model.
East Star Resources, Can Partners Build the Value Without Diluting the Story?
East Star’s model has become much clearer over the past six months. Rather than trying to fund several large exploration and development programmes itself, the company has brought in partners with the balance sheets and technical capability to do much of the heavy lifting. At Verkhuba, Xinhai is expected to fund an estimated US$65 million development programme while East Star retains a 30% interest at production. That structure gives the company exposure to a potentially substantial copper project without forcing it to carry the full cost of development.
The operational work has also started to move. By August, seven diamond holes totalling more than 1,350 metres had been completed at Verkhuba, with a second rig mobilised to accelerate the programme. The project already hosts a JORC resource of around 20.3 million tonnes grading 1.16% copper, 1.54% zinc and 0.27% lead, meaning the next phase is about extending and upgrading an existing resource rather than starting from scratch. That gives the drilling a more immediate development purpose than a typical greenfield campaign.
East Star has also widened the model beyond Verkhuba. The company signed a second copper joint venture at Rulikha, where third parties are expected to fund development and East Star retains at least 25% at production. At the same time, Endeavour Mining can earn 51% of East Star’s Kazakhstan gold joint venture by spending US$5 million over two years, with reconnaissance already completed across 15 priority targets and additional licence applications covering more than 930 square kilometres. East Star is therefore building several routes to value at once, while trying to keep its own capital requirements relatively contained.
The attraction of that approach is obvious, but so is the test. Partner funded programmes only create value for East Star if the projects advance far enough and fast enough for its retained interests to become economically meaningful. The next evidence investors need is continued drilling progress at Verkhuba, movement at Rulikha and signs that the Endeavour gold portfolio is narrowing towards targets capable of supporting serious follow up work. If that happens, East Star’s model could begin to show how a junior explorer can increase exposure without funding every stage itself.
Forgent, From Corporate Reinvention to an Accelerating Drill Programme
Forgent has taken a much more direct route. The company spent the first part of 2026 reshaping itself around a new portfolio and then moved quickly to put drill rigs into the ground. It raised around £1.3 million and acquired 51% of the Peak Hill project before later increasing its ownership to 99%. The result is that Forgent is now being judged much more on drill results than on corporate restructuring.
Phase 1 at Peak Hill was completed in July, with 40 holes drilled for around 2,680 metres. Early assay results included an intercept of 2m at 3.68g/t gold, which was strong enough for management to follow up aggressively rather than pause between campaigns. That is exactly the kind of result an explorer wants at this stage, not because one intercept proves a deposit, but because it gives the next phase a clear technical reason to exist.
The Phase 2 programme has therefore expanded quickly. By September, Forgent had enlarged the campaign to around 144 holes for approximately 9,540 metres, including additional work around the Curley’s target where the stronger Phase 1 mineralisation was identified. A further 12 holes had already been completed around Curley’s by 21st September. The company is effectively trying to answer the question of scale before investor attention moves on.
Forgent also has Mount Sholl in the background, giving it exposure to a more advanced nickel, copper and PGE asset alongside the gold focused drilling at Peak Hill. That diversification gives the portfolio more than one route to progress, but it also means management has to show that capital and attention are being allocated coherently rather than spread too thinly. The near term test remains simple, Phase 2 needs to show that the early gold results can be repeated across enough width, grade and strike to support a more substantial discovery story. If that evidence arrives, the corporate reinvention of early 2026 will have something more concrete behind it than a new name and a new asset base.
Bezant Resources, The Final Step From Developer to Producer
Bezant has moved further along the development curve than the other mining companies in this group. Its Hope & Gorob copper gold project in Namibia is no longer mainly a planning exercise, with construction, mining and plant work now underway. The company increased its project interest from 70% to 90% in March and raised £2.07 million to help fund the acquisition, mine development and plant improvements. By that stage, first copper gold concentrate was already being targeted for the second half of 2026.
The financing structure became clearer in June when Bezant completed definitive agreements with Hartree Metals for a US$7 million secured prepayment facility. Hartree also agreed to purchase 100% of copper concentrate produced over the life of the operation on market terms. That removes one major commercial question because Bezant now has both development finance and a defined customer for future output. The trade-off is that the project enters production with a more complex financing structure that investors will need to follow closely.
Physical development has also accelerated. In August, the first blast liberated around 20,000 tonnes of material, including approximately 2,000 tonnes of commercially viable mineralisation, while by early September run of mine stockpiles were ahead of plan. The processing plant had also received its C1 civil and structural completion certificate, with mechanical completion expected during September and first run of mine ore processing targeted for the same month. Bezant is therefore approaching the point where tonnes processed and concentrate produced matter more than development schedules.
There is already discussion of what comes after the initial operation. Management is reviewing a Phase II expansion that could incorporate material previously considered sub economic and potentially extend project life towards around 35 years. Hartree has also committed a further US$5 million towards accelerated ownership of the processing plant, further tying the financier into the project. Before that longer term potential matters, however, Bezant first has to show that Hope & Gorob can commission successfully, produce saleable concentrate and begin generating the cash flow expected from the development plan.
Physiomics, Can Contract Momentum Become Sustainable Growth?
Physiomics has followed a very different route, but its recent progress is just as measurable. After the shareholder driven board changes in April, the company carried out a strategic and operational reset aimed at sharpening its commercial focus and moving towards breakeven. By June, management said Physiomics had built its largest commercial pipeline to date and had identified cost savings as part of that path. The question now is whether that stronger pipeline can convert into repeatable revenue rather than another short burst of contract wins.
So far, the commercial evidence has been encouraging. In May, Physiomics announced more than £345,000 of new contracts across modelling, simulation, biometrics and data science work. In July, it added a further £200,000 plus, including follow on biometrics work and a new modelling contract with a Boston based biotech developing cancer immunotherapies. That progression suggests the company is winning work across several service lines rather than relying on one large customer or one product.
September strengthened the trend again. New awards worth more than £205,000 took aggregate contract wins since May to more than £750,000 in just over four months. Physiomics said that figure was equivalent to around 95% of the revenue reported for the entire 2024 to 2025 financial year. That comparison gives investors a much more useful measure of momentum than simply counting the number of contract announcements.
The next test is whether those awards flow through into recognised revenue, margins and ultimately profitability. Contract value is not the same thing as immediate revenue because projects can run over several months or even into future financial years, but the scale and frequency of recent wins give Physiomics a stronger base than it had earlier in the year. The company is also seeing increasing interest in its specialist modelling capabilities from international research and clinical collaborations. If the commercial pipeline continues converting at this pace while costs remain controlled, the story can start moving from recovery and restructuring towards a more credible growth model.
The Next Numbers That Actually Matter
The next stage for East Star is about proving that its partner funded model can keep advancing without losing momentum. At Verkhuba, investors will be watching drill results from the expanded programme, where more than 1,350 metres had already been completed by August and a second rig had been mobilised. At Rulikha, the key question is whether the newly signed joint venture begins moving quickly into meaningful field work, while the Endeavour gold programme needs to narrow its 15 priority targets into a smaller number of drill ready prospects. The real proof will be whether outside capital continues translating into measurable asset progression.
For Forgent, the next numbers are much more geological. Phase 2 at Peak Hill has expanded to around 9,540 metres, so the market now needs to see whether the early 2m at 3.68g/t gold intercept can be repeated across meaningful widths and strike length. The quantity of drilling is already large enough that the next assay batches should start showing whether Curley’s and the wider Peak Hill area contain isolated high grade hits or something that can support a larger mineralised system. That distinction will matter far more than another expansion of the drill programme.
Bezant’s milestones are even easier to measure because Hope & Gorob is approaching production. Investors should now focus on tonnes processed, concentrate grades, recovery rates, first sales and the amount of cash generated against the project’s financing obligations. The plant was expected to begin processing first run of mine ore during September, while stockpiles were already reported to be ahead of plan. Once commissioning begins, operational data should replace development milestones as the most important measure of progress.
Physiomics has an equally clear commercial scorecard. The company has announced more than £750,000 of contract wins since May, but the next question is how quickly those awards convert into recognised revenue and whether gross margins improve at the same time. Repeat work from existing clients, new international customers and progress towards the stated breakeven objective will matter more than simply adding another contract headline. The next financial results should therefore be especially useful because they will show how much of the recent momentum has actually reached the income statement.
Execution Changes the Risk, It Does Not Remove It
The common thread across all four companies is that the original investment story has become more measurable. East Star has major partners funding large parts of its portfolio, Forgent has moved rapidly into repeated drilling, Bezant is approaching physical production, and Physiomics has built a visibly stronger commercial pipeline. That is progress, but it also means each company is moving into a new category of risk rather than escaping risk altogether.
For East Star, the main uncertainty is execution by partners and whether retained interests ultimately translate into material value. Xinhai’s proposed Verkhuba programme is estimated at around US$65 million, while Endeavour can earn into the gold portfolio by spending US$5 million over two years. Those structures reduce East Star’s direct funding burden, but they also mean progress depends partly on third parties continuing to commit capital and technical resources.
Forgent and Bezant face different tests. Forgent must show that a rapidly expanding exploration programme produces enough grade, continuity and scale to justify further capital, while Bezant must now prove that mine construction and financing convert into reliable production rather than commissioning delays or cost pressure. Hope & Gorob’s US$7 million prepayment facility and 100% life of mine concentrate offtake provide a clear commercial framework, but they also raise the importance of meeting operational expectations.
Physiomics faces the most familiar commercial risk of the four, converting sales momentum into a profitable business. More than £750,000 of recent awards is meaningful relative to its historic revenue base, but contract announcements alone do not guarantee sustainable margins or cash generation. That is why the next phase should be more informative than the last: all four companies now have clearer evidence, clearer milestones and clearer ways to disappoint. The opportunity may have become easier to understand, but the execution still has to follow.
Disclaimer: The information presented in this article represents the opinions and research of the author and is provided for informational purposes only. It is not intended to be, nor should it be interpreted as, financial, investment, or legal advice. Investors are encouraged to perform their own due diligence and consult with qualified financial advisors before making any investment decisions. Investing in small-cap stocks involves significant risks, and past performance is not indicative of future results. The author and publisher are not liable for any financial losses or actions taken based on the content of this article.
